Open Access
CC BY-NC-ND 4.0 · Endosc Int Open 2021; 09(11): E1712-E1719
DOI: 10.1055/a-1546-8727
Original article

Colon capsule endoscopy in colorectal cancer screening: Interim analyses of randomized controlled trial CareForColon2015

Autoren

  • Ulrik Deding

    1   Department of Surgery, Odense University Hospital, Svendborg, Denmark
    2   Department of Clinical Research, University of Southern Denmark, Odense, Denmark
  • Thomas Bjørsum-Meyer

    1   Department of Surgery, Odense University Hospital, Svendborg, Denmark
    2   Department of Clinical Research, University of Southern Denmark, Odense, Denmark
  • Lasse Kaalby

    1   Department of Surgery, Odense University Hospital, Svendborg, Denmark
    2   Department of Clinical Research, University of Southern Denmark, Odense, Denmark
  • Morten Kobaek-Larsen

    1   Department of Surgery, Odense University Hospital, Svendborg, Denmark
    2   Department of Clinical Research, University of Southern Denmark, Odense, Denmark
  • Marianne Kirstine Thygesen

    1   Department of Surgery, Odense University Hospital, Svendborg, Denmark
    2   Department of Clinical Research, University of Southern Denmark, Odense, Denmark
  • Jeppe Buur Madsen

    3   Department of Biochemistry and Immunology, University Hospital Lillebaelt, Vejle, Denmark
  • Rasmus Kroijer

    4   Department of Surgery, Hospital of Southwest Jutland, Esbjerg, Denmark
  • Gunnar Baatrup

    1   Department of Surgery, Odense University Hospital, Svendborg, Denmark
    2   Department of Clinical Research, University of Southern Denmark, Odense, Denmark

Abstract

Background and study aims The Danish CareForColon2015 trial, launched in 2020 as part of the Danish Colorectal Cancer Screening program, is the largest randomized controlled trial to date on colon capsule endoscopy (CCE). This paper presents the interim analysis with the objective of ensuring the safety of patients in the intervention group and evaluating the clinical performance of the trial’s predefined clinical parameters.

Patients and methods We evaluated the initial 234 CCEs according to quality, safety, and completion. The participation rates and preference distribution of all individuals invited were analyzed and sample size calculations were adjusted.

Results Fecal immunochemical test and diagnostic participation rates were 62.1 % and 91.1 %, respectively. The completion rate for CCEs was 67.9 % and the rate of conclusive investigations was 80.3 %. The polyp detection rate (PDR) was high (73.5 %), only two (0.85 %) technical failures in 234 videos were observed, and six suspected cancers were identified (2.6 %). No major adverse events were recorded. The required number of invitations had been underestimated due to inaccurate assumptions in sample size calculations.

Conclusions The trial was efficient and safe in terms of CCE quality and time to diagnostic investigation. Participation rates and PDRs were high. The proportion of suspected cancers was lower than expected and will be followed. The completion rate for CCEs was acceptable but lower than expected and the CCE procedure was reviewed for potential improvements and Resolor was added to the regime. The number of invitations for the intervention group of the trial has been adjusted from 62,107 to 185,153.



Publikationsverlauf

Eingereicht: 30. März 2021

Angenommen: 22. Juni 2021

Artikel online veröffentlicht:
12. November 2021

© 2021. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany